Literature DB >> 832508

Pharmacokinetic study of intravenous rifampicin.

V Nitti, R Virgilio, M R Patricolo, A Iuliano.   

Abstract

The time course of the serum and urine concentrations of rifampicin were evaluated during and after administration of an intravenous preparation of the antibiotic. 300, 450 and 600 mg dose levels of the antibiotic were evaluated, all being given as intravenous infusion after solution in 500 ml of glucose, the infusion lasting 3 h. The results have shown that the serum level curves and the kinetic parameters calculated on them do not differ to any major extent from those corresponding to the same doses given orally. No changes of relevance in the half-life values were observed between doses. Changes in serum bilirubin levels were observed with a pattern similar to that commonly seen with oral administration of rifampicin.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 832508     DOI: 10.1159/000221963

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  7 in total

Review 1.  Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.

Authors:  W J Burman; K Gallicano; C Peloquin
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  Pharmacokinetics of oral and intravenous rifampicin during chronic administration.

Authors:  U Loos; E Musch; J C Jensen; G Mikus; H K Schwabe; M Eichelbaum
Journal:  Klin Wochenschr       Date:  1985-12-02

Review 3.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

4.  Radiosynthesis and bioimaging of the tuberculosis chemotherapeutics isoniazid, rifampicin and pyrazinamide in baboons.

Authors:  Li Liu; Youwen Xu; Colleen Shea; Joanna S Fowler; Jacob M Hooker; Peter J Tonge
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

5.  Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions.

Authors:  Alvaro A Ordonez; Hechuan Wang; Gesham Magombedze; Camilo A Ruiz-Bedoya; Shashikant Srivastava; Allen Chen; Elizabeth W Tucker; Michael E Urbanowski; Lisa Pieterse; E Fabian Cardozo; Martin A Lodge; Maunank R Shah; Daniel P Holt; William B Mathews; Robert F Dannals; Jogarao V S Gobburu; Charles A Peloquin; Steven P Rowe; Tawanda Gumbo; Vijay D Ivaturi; Sanjay K Jain
Journal:  Nat Med       Date:  2020-02-17       Impact factor: 53.440

Review 6.  Clinical pharmacokinetics of the antituberculosis drugs.

Authors:  M R Holdiness
Journal:  Clin Pharmacokinet       Date:  1984 Nov-Dec       Impact factor: 6.447

7.  Development and Evaluation of Physiologically Based Pharmacokinetic Drug-Disease Models for Predicting Rifampicin Exposure in Tuberculosis and Cirrhosis Populations.

Authors:  Muhammad F Rasool; Sundus Khalid; Abdul Majeed; Hamid Saeed; Imran Imran; Mohamed Mohany; Salim S Al-Rejaie; Faleh Alqahtani
Journal:  Pharmaceutics       Date:  2019-11-05       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.